Metastatic Cervical Cancer Clinical Trial
Official title:
Randomized, Double-Blind, Phase III Trial of Chemotherapy Plus the Transcriptional Therapy Hydralazine and Magnesium Valproate Versus Chemotherapy Plus Placebo in Recurrent and Metastatic Cervical Cancer.
The current standard for recurrent, persistent or metastatic cervical cancer is palliative
chemotherapy with cisplatin topotecan, however, the results need to be improved. Epigenetic
aberrations play an important role in cancer progression by silencing growth regulatory
genes and there is now evidence that inhibitors of DNA methylation and HDAC inhibition
synergize the cytotoxicity of chemotherapy.
Objective. To determine the superiority of epigenetic therapy with hydralazine and valproate
plus standard cisplatin topotecan against placebo plus cisplatin topotecan upon
progression-free survival.
Hypothesis. Hydralazine and magnesium valproate associated to cisplatin topotecan will
increase progression-free survival from 4.6 to 7.6 months as compared with the same regimen
of chemotherapy plus placebo.
Randomized, double-blind phase III trial. A total of 143 patients (alpha 0.5, power 0.8)with metastatic, persistent or recurrent cervical cancer without previous systemic treatment will be randomized to cisplatin topotecan + placebo or cisplatin topotecan hydralazine valproate for 6 courses every 3 weeks. Patients will receive an oral dose of hydralazine of 182mg (rapid) or 83mg (slow) according to the acetylator phenotype in a single daily dose and magnesium valproate at an oral dose of 40mg/Kg t.i.d. Both drugs in a slow-release formulation. Experimental drugs or placebo will start from seven days before day 1 of chemotherapy until the end of the sixth course. ;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05446883 -
QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT04266886 -
Self-Hypnosis for the Enhanced Recovery After Surgery in Patients With Gynecologic Cancer
|
N/A | |
| Recruiting |
NCT04865887 -
Pembrolizumab and Lenvatinib in Advanced Cervical Cancer
|
Phase 2 | |
| Completed |
NCT00430781 -
Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer
|
Phase 2 | |
| Terminated |
NCT03786107 -
HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib
|
||
| Recruiting |
NCT06238635 -
Dostarlimab and Cobolimab in Advanced Cervical Cancer
|
Phase 2 | |
| Withdrawn |
NCT05614453 -
Tislelizumab in Combination With Sitravatinib for Recurrent/Metastatic Cervical Cancer After Platinum-Based Chemotherapy
|
Phase 2 | |
| Terminated |
NCT03277482 -
Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer
|
Phase 1 | |
| Completed |
NCT04380805 -
A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer
|
Phase 2 | |
| Completed |
NCT03816553 -
SHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer
|
Phase 2 | |
| Withdrawn |
NCT04943627 -
Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)
|
Phase 3 | |
| Recruiting |
NCT06313268 -
Safety of Effivia®, a Bevacizumab Biosimilar
|
||
| Terminated |
NCT04230954 -
Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer
|
Phase 2 |